ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1437

Journal of Clinical & Experimental Pathology received 1437 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

Behavior of advanced gastrointestinal stromal tumor in apatient with von-Recklinghausen disease: Case report

4th International Conference and Exhibition on Pathology

Samer Sawalhi

Posters-Accepted Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.017

Abstract
Gastrointestinal stromal tumors (GISTs) represent a malignant gastrointestinal tumor of neurofibromatosis type1 (NF1) Von Recklinghausen disease. In the current case, we report a 27-year-old woman with NF1, who presented with a lower abdominal mass, symptomatic anaemia, and significant weight loss. We employed multiple approaches to assess the tumor behavior, including computed tomography (CT) scan, surgical tumor resection, histological and immunohistochemical analysis andgene sequencing. Additionally, the patient was given Imatinib mesylate (Gleevec) as adjuvant therapy. CT scan delineated a large thick wall cavity lesion connecting to the small bowel segment. Resection of the tumor yielded a mass of 17 cm Ã? 13 cm with achievement of safety margins. The diagnosis was GIST, confirmed by immunohistochemical expression of CD117, CD34, and Bcl-2. Sequencing revealed no mutations in either KIT or platelet-derived growth factor receptor-alpha, genes which are mutated in over 85% of sporadic GIST cases. Further, there was no evidence of recurrence, metastasis or metachronous GIST for over three years in our patient. From our analyses, we believe selective genotyping is advisable for high risk patients to predict potential tumor behavior.
Biography
Samer Sawalhi has completed his Bachelor degree from Baghdad University, and then he joined the general surgical program, after that he worked as a surgical specialist in King Hussein Cancer Center. In 2010, He was appointed as Assistant Professor-surgical department and permanent researcher in the Center of Genetics and Inherited Diseases in Taibah University-Saudi Arabia. He is interested in Onco-genetic mutation in surgical cancer patients. He has published 10 papers in reputed journals and serving as an Editorial Board Member in 5 Journals. Recently, he is doing Minimal invasive thoracic surgery fellowship at Dalhousie University-Thoracic surgery department.
Top